Mucormycosis

Indication for Amphotericin B

Population group: Suitable for both men and women, only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

For this indication, competent medicine agencies globally authorize below treatments:

5 mg/kg once daily

Route of admnistration

Intravenous

Defined daily dose

5 - 5 mg per kg of body weight

Dosage regimen

From 5 To 5 mg per kg of body weight once every day

Detailed description

The recommended starting dose is 5 mg/kg/day. The duration of therapy should be determined on an individual basis. Courses of up to 6–8 weeks are commonly used in clinical practice; longer durations of therapy may be required for deep seated infections or in cases of prolonged courses of chemotherapy or neutropenia.

Although doses greater than 5 mg/kg and up to a maximum of 10 mg/kg have been used in clinical trials and clinical practice, data on the safety and efficacy of amphotericin B for the treatment of mucormycosis at these higher doses are limited. Therefore, a benefit:risk assessment should be made on an individual patient level to determine whether the potential benefits of treatment are considered to outweigh the known increased risk of toxicity at higher amphotericin B doses.

Dosage considerations

Amphotericin B should be administered by intravenous infusion over a 30-60 minute period. For doses greater than 5mg/kg/day, intravenous infusion over a 2 hour period is recommended.

Active ingredient

Amphotericin B is a macrocyclic, polyene antifungal antibiotic produced by Streptomyces nodosus. The molecule is thought to act by binding to sterols in the fungal cell membrane, with a resulting change in membrane permeability, allowing leakage of a variety of small molecules.

Read more about Amphotericin B

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner